Subscribe to DrG's Free Newsletter |
|
We DO NOT share our email list with anyone. DrG is very respectful of your right to privacy.
For a one-year hard copy subscription, sent through the U.S. mail, send $18 to Healthy Choices for Mind and Body, P.O. Box 19938, Sacramento, CA 95819. All email subscriptions and downloads from the website are free.
DrG's Healthy Choices for Mind and Body is a registered non-profit charitable organization established to promote a world in which all people practice healthy lifestyles. Your contributions are tax deductable.
DrG's Medisense Feature Article
16122-Med_Metab_2
Medication Metabolism: Sex and
Race Variability
by Ann Gerhardt, MD
December 2016
Print Version
I last wrote about drug metabolism, the mechanisms and rate by which
our bodies degrade and eliminate toxins, medications and naturally
occurring or man-made chemical substances in March 2009 (
DrG’s MediSense Volume 4-1).
I discussed inter-individual
differences, but didn’t mention sexual or racial
differences.
The rapidity with which we clear substances out of our system depends
on enzymes that do the clearing. Since it takes a gene to make an
enzyme, the amount and activity of those enzymes depend on our genetic
make-up. Sex and race are major hereditary differences, and it
turns out that they are linked to major differences in ability to
degrade a whole variety of substances.
With slower clearance, blood levels build up, a substance’s
effect intensifies and unpleasant effects may appear at lower
doses. With rapid clearance, a typical dose often has no effect,
good or bad. There are many substance-clearing enzymes, each with
a different function. There’s no way to predict clearance, since
someone who makes a lot of one enzyme, may make little of another.
It turns out that women are much more likely to clear substances more
slowly out of their bodies. This is probably why more women than
men identify themselves as ‘chemically sensitive.’
Many women require lower doses of anti-psychotics, opiate pain killers
and digoxin. Compared to men, different anti-depressants work
better, aspirin protects better against stroke and less well against
heart attack and they respond better to beta-blocker blood pressure
medicine. Women are 50-75% more likely to report an adverse
effect of a medication.
Race is important since genetic mutations that either speed up or slow
down clearance get passed down from one generation to the next.
We know that African Americans often need higher doses of many
medications to be effective, and that the different races respond
better to different blood pressure medications, but that’s not
absolute. We don’t yet know how to predict what a
particular individual’s response will be, since the genetic
pattern of each person in a particular racial group is not
identical.
Which brings us to the problem of interpreting studies which were used
to prove that a new drug provides a benefit that outweighs risk.
Until recently most such studies included mostly or all males, who were
mostly Caucasian. Pregnant women were always and women of
child-bearing age were almost always excluded. Very few African
Americans, Hispanics and Asians were included. How is one to know
if a given drug even works in women or non-Caucasian races if they
weren’t studied?
Though Congress passed the 1993 National Institutes of Health (NIH)
Revitalization Act that required enrollment of women in phase 3 drug
trials, women made up less than one-quarter of all patients enrolled in
46 clinical trials completed in 2004. There are no requirements
for racial diversity in clinical trials.
There has been more alarm, leading to more analysis concerning gender
than racial disparity in drug studies. A 2006
study published in Genome Research reported that
the levels of gene expression differed between male and female mice for
72 percent of active genes in the liver, 68 percent of those in fat,
55.4 percent of the ones in muscle, and 13.6 percent of genes in the
brain. Women receive the standard influenza vaccine dose, even
though they require half as much for the same level of
protection. Blood and tissue concentrations of eleven new
medications in women are up to 40 percent off of levels in the average
Caucasian male.
Lately the NIH and scientific journals are pushing scientists to
analyze results by gender, age and racial subgroups, but often a trial
doesn’t have enough of each group to lead to meaningful
analysis. So doctors blithely prescribe the studied starting dose
to everyone and hope that it helps without hurting. Regardless of
what starting dose a doctor chooses, patients should speak up and
doctors should listen, to gauge how correct that dose was. ╣